Skip to main content
KPTI logo

KPTI · Karyopharm Therapeutics Inc. · Documents

Track KPTI — free
$0.02 +0.00 (+3.45%) At close · Nov 11 Play latest call Q2 2026 earnings call transcript
Market Cap
$408,266
Shares
22.68M
Volume · Nov 11 8.28M Avg daily vol (3M) 8.53M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $146.07M up 0.6% 10-K filed Feb 13, 2026 Quarterly report FY2026 Q2 Revenue $33.43M down 11.9% 10-Q filed Aug 13, 2026 Latest results Financial results 8-K filed Aug 13, 2026 Earnings call Q2 2026 earnings call Held Aug 13, 2026
2026
Nov 13
Late filing notice NT 10-Q
Bankruptcy delays quarterly filing; Nasdaq suspends trading

Karyopharm Therapeutics Inc. filed Chapter 11 on November 2, 2026, cannot file its Form 10-Q, and Nasdaq suspended trading on November 11, 2026. Its plan cancels equity without distribution, with Ayrmid transaction expected to close in first quarter of 2027.

5 source passages
Karyopharm Therapeutics Inc. (the “Company”) has determined that it is unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 (the “Quarterly Report”) by the prescribed filing date or the five-day extension permitted by the rules of the Securities and Exchange Commission (the “SEC”). As previously announced, on November 2, 2026, the Company and its subsidiary KPT Texas LLC (together with the Company, the “Debtors”) filed voluntary petitions (the “Bankruptcy Petitions”) under Chapter 11 of title 11 of the United States Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the Southern District of Texas, Houston Division (such court, the “Court” and such cases, the “Cases”). On November 11, 2026, the Nasdaq Stock Market (“Nasdaq”) suspended trading of the Company’s common stock. The Prepackaged Plan provides that holders of the Company’s common stock and the 0% Series A Convertible Perpetual Preferred Stock will not receive any payment or other distribution on account of such securities. The Company expects the Ayrmid transaction to close in the first quarter of 2027, subject to the conditions described in the Restructuring Support Agreement and the Prepackaged Plan. Open the document at this passage
Nov 5
Current report 8-K Events of Nov 4
Nasdaq delisting follows Karyopharm Chapter 11 filing

After Karyopharm Therapeutics Inc. filed Chapter 11 petitions on November 2, 2026, Nasdaq notified it that securities will be delisted. Trading will suspend November 11, 2026; it will not appeal and expects existing equity securities to have no value.

Delisting notice or listing transfer
5 source passages
As previously disclosed, on November 2, 2026, Karyopharm Therapeutics Inc. (the “Company”) and its subsidiary, KPT Texas LLC (together with the Company, the “Debtors”) filed voluntary petitions (the “Bankruptcy Petitions”) under Chapter 11 of title 11 of the United States Code On November 4, 2026, the Company received written notice (the “Delisting Notice”) from the staff of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that, as a result of the Bankruptcy Petitions and in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, the staff of Nasdaq determined that the Company’s securities will be delisted from Nasdaq. Trading of the Company’s common stock will be suspended on Nasdaq at the opening of business on November 11, 2026 and a Form 25-NSE will be filed with the Securities and Exchange Commission, which will remove the securities from listing and registration on Nasdaq. The Company will not appeal this determination. In particular, the Company expects that its existing equity securities will have no value and that holders of such securities will experience a complete loss on their investment. Open the document at this passage
Nov 2
Current report 8-K
Ayrmid merger advances through Chapter 11, equity expected worthless

Karyopharm Therapeutics Inc. plans a merger with Ayrmid Ltd. and filed Chapter 11 petitions. The deal is expected to close in the first quarter of 2027 with up to $55 million in DIP financing; equity is expected to have no value.

Regulation FD disclosure
5 source passages
Karyopharm Therapeutics Inc. ("Karyopharm") announced today it has entered into a Restructuring Support Agreement with its existing lenders and noteholders and other key stakeholders, which provides for a merger between Ayrmid Ltd. ("Ayrmid") and a reorganized Karyopharm (the "Transaction"). To implement the Transaction, Karyopharm has filed voluntary petitions under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the Southern District of Texas. The Transaction is expected to close in the first quarter of 2027, subject to the conditions described in the Chapter 11 plan. In connection with this process, Karyopharm has secured commitments for up to $55 million in debtor-in-possession ("DIP") financing from its existing secured lenders. The Company expects that its existing equity securities will have no value and that holders of such securities will experience a complete loss on their investment. Open the document at this passage
Oct 22
Current report 8-K
Other events

Karyopharm Therapeutics Inc. further extended the end of its forbearance period from 11:59 p.m., Eastern time, on October 22, 2026 to 11:59 p.m., Eastern time, on November 1, 2026, absent earlier termination.

Oct 14
Current report 8-K Events of Oct 13
Other events

On October 13, 2026, Karyopharm Therapeutics Inc. extended the date the Forbearance Period will end, absent earlier termination, from 11:59 p.m., Eastern time, on October 15, 2026 to 11:59 p.m., Eastern time, on October 22, 2026.

Aug 31
Current report 8-K
Other events AI summary on its way
Aug 13
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $33.43M ▼ 11.9% Net loss $67.02M Diluted EPS -$2.32
Jul 31
Current report 8-K Events of Jul 30
Other events AI summary on its way
May 14
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $35.07M ▲ 16.8% Net loss $22.39M Diluted EPS -$1.24
Mar 27
Current report 8-K
Other events AI summary on its way
Feb 13
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $146.07M ▲ 0.6% Net loss $196.04M Diluted EPS -$17.93
Jan 9
Proxy statement DEF 14A Meeting Feb 18, 2026
Proxy statement AI summary on its way
2025
Showing 1–50 of 193 documents
Key facts CIK 1503802 CUSIP 48576U205 13F (30d) 102 filings 86 filers Visit website Investor relations